PMID- 32983715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 25
TI  - Intravenous Immunoglobulin-Associated Elevation of Liver Enzymes in Neurological 
      Autoimmune Disorder: A Case Series.
PG  - e10020
LID - 10.7759/cureus.10020 [doi]
LID - e10020
AB  - Intravenous immunoglobulin (IVIG) is used in the treatment of a variety of 
      autoimmune neurological disorders and is generally regarded as safe. We present a 
      case series where IVIG causes transaminitis. The adverse effects are mostly due 
      to the stabilizing agent used to prepare the IVIG (e.g., maltose in this series). 
      While the adverse effects are usually self-limiting, physicians should be 
      cautious in administering an IVIG preparation to these patients.
CI  - Copyright (c) 2020, Behera et al.
FAU - Behera, Anupama
AU  - Behera A
AD  - Internal Medicine, All India Institute of Medical Sciences, Bhubaneswar, IND.
FAU - Guru, Satyabrata
AU  - Guru S
AD  - Trauma and Emergency/Internal Medicine, All India Institute of Medical Sciences, 
      Bhubaneswar, IND.
LA  - eng
PT  - Case Reports
DEP - 20200825
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7515744
OTO - NOTNLM
OT  - intravenous immunoglobulin
OT  - neurological autoimmune disorders
OT  - transaminitis
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
PMCR- 2020/08/25
CRDT- 2020/09/28 05:43
PHST- 2020/09/28 05:43 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
PHST- 2020/08/25 00:00 [pmc-release]
AID - 10.7759/cureus.10020 [doi]
PST - epublish
SO  - Cureus. 2020 Aug 25;12(8):e10020. doi: 10.7759/cureus.10020.